Boehringer Ingelheim

Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim's KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- The "Global Animal Health Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to...

/PRNewswire/ -- Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure...

Through this collaboration, Boehringer Ingelheim and Google plan to focus on implementing quantum computing in pharmaceutical research and development, including molecular dynamic simulations.

We're used to formal clothing expensive hotels and meeting venues that solitary confinement cells look spacious, with the offer of $20 coffees (if spending a minimum of $100), but this year, things are very different.

Through a new partnership with Google, Boehringer Ingelheim hopes to harness quantum computing to simulate the body's molecular mechanics.

Boehringer Ingelheim has struck a deal to buy NBE-Therapeutics for €1.2 billion ($1.5 billion) to add a ROR1-directed antibody-drug conjugate (ADC) to its pipeline. The deal comes one month after Merck agreed to pay $2.8 billion to acquire VelosBio for its anti-ROR1 ADC.

Boehringer Ingelheim teamed up with German biotech Labor Dr. Merk & Kollegen in 2015 on viral-based therapies. Five years on, it's swallowing up its partner, a move it thinks will boost development of its oncolytic, or cancer-killing viruses, and cancer vaccines. The companies did not disclose financial details.

/PRNewswire/ -- Dados da Organização Mundial de Saúde (OMS) indicam que o câncer de pulmão é a neoplasia mais incidente no mundoi. Em 2018, foram mais de 2...

/PRNewswire/ -- Seven individuals living with type 2 diabetes and representing a wide range of experiences have been selected as the 2020-21 national...

/PRNewswire/ -- On November 9, 2020, Bridge Biotherapeutics (288330 KQ) reported to the Korea Stock Exchange that the Company and Boehringer Ingelheim have...

Boehringer Ingelheim plans to bring innovative products catering mainly to pets and poultry segment in India, as it expects these verticals to grow in a robust manner over the next few years

The COVID-19 pandemic has thrown a curve ball at the global economy, and the biopharma industry is no exception. Companies are scrambling to develop tests, treatments and vaccines for the disease, while making sure not to neglect their pipelines. We caught up with Ioannis Sapountzis, Boehringer Ingelheim's global head of business development and licensing, to see how the German pharma is handling this.

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes is the use of well-characterized small chemical modulators of protein function. The new EUbOPEN consortium aims

Boehringer Ingelheim is boosting its early-stage bets while also inking a new deal to work on a therapy against a leading cause of blindness.

Boehringer Ingelheim Acquires Northern Biologics' Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio - read this article along with other careers information, tips and advice on BioSpace

Boehringer Ingelheim Collaborates with CDR-Life to Develop Antibody Fragment-based Therapeutics for Geographic Atrophy, a Leading Cause of Blindness Worldwide - read this article along with other careers information, tips and advice on BioSpace

For the fifth year, Boehringer Ingelheim sponsors the European PRRS Research Award to support applied research for improved control of the PRRS swine disease (Porcine Reproductive and Respiratory Syndrome). Research proposals for the 2020 European PRRS Research Award can be submitted until 1 July 2020. Boehringer Ingelheim will provide three grants of 25,000 euros each to fund research proposals that will generate new and relevant data to better understand this devastating and costly disea...